Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma

Lung Cancer

Volumn 39, Issue 3, 2003, Pages 339-345

  Bakhshandeh, A ^a   Bruns, I ^a   Traynor, A ^b   Robins, H I ^b   Eberhardt, K ^c   Demedts, A ^c   Kaukel, E ^d   Koschel, G ^d   Gatzemeier, U ^e   Kohlmann, Th ^a   Dalhoff, K ^a   Ehlers, E M ^a   Gruber, Y ^a   Zumschlinge, R ^f   Hegewisch Becker, S ^g   Peters, S O ^a   Wiedemann, G J ^h  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Zentralkrankenhaus Bremen Ost   (Germany)

^d Asklepios Klinik Harburg   (Germany)

^e KRANKENHAUS GROSSHANSDORF   (Germany)

^f Krankenhaus Trostberg   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h Oberschwaben Klinik   (Germany)

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Whole body hyperthermia

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTHERMIC THERAPY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037374232     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00536-6     Document Type: Article

References (34)

1. Bitton M. The epidemiology of mesothelioma. Semin. Oncol. 29:2002;18-25.
2. Ceresoli G.L., Locati L.D., Ferreri A.J., et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 34:2001;279-287.
3. Butchart E.G. Contemporary management of malignant pleural mesothelioma. Oncologist. 4:1999;488-500.
4. Ong S.T., Vogelzang N.J. Chemotherapy in malignant pleural mesothelioma: a review. J. Clin. Oncol. 14:1996;1007-1017.
5. Berghmans T., Paesmans M., Lalami Y., et al. Chemotherapy for malignant mesothelioma: a quantitative and qualitative overview of the literature. Proc. Am. Soc. Clin. Oncol. 18:1999;481a. abstract #1858.
6. Dahl O., Dalene R., Schem B.C., Mella O. Status of clinical hyperthermia. Acta Oncol. 38:1999;863-873.
7. Wiedemann G.J., Robins H.I., Katschinski D.M., et al. Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status. Anticancer Res. 17:1997;2899-2902.
8. Flentje M., Flentje D., Sapareto S.A. Differential effect of hyperthermia on murine bone marrow normal colony-forming units and AKR and L1210 leukemia stem cells. Cancer Res. 44:1984;1761-1766.
9. Robins H.I., Steeves R.A., Clark A.W., Martin P.A., Miller K., Dennis W.H. Differential sensitivity of AKR murine leukemia and normal bone marrow cells to hyperthermia. Cancer Res. 43:1983;4951-4955.
10. Robins H.I., Jonsson G.G., Jacobson E.L., Schmitt C.L., Cohen J.D., Jacobson M.K. Effect of hyperthermia in vitro and in vivo on adenine and pyridine nucleotide pools in human peripheral lymphocytes. Cancer. 67:1991;2096-2102.
11. Katschinski D.M., Robins H.I., Schad M., Frede S., Fandrey J. Role of tumor necrosis factor a in hyperthermia-induced apoptosis of human leukemia cells. Cancer Res. 59:1999;3404-3410.
12. Westermann A.M., Grosen E.A., Katschinski D.M., et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur. J. Cancer. 37:2001;1111-1117.
13. Ehlers E.M., Kuhnel W., Wiedemann G.J. Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line. J. Cancer Res. Clin. Oncol. 128:2002;65-72.
14. Katschinski D.M., Jacobson E.L., Wiedemann G.J., Robins H.I. Modulation of VP-16 cytotoxicity by carboplatin and 41.8 degrees C hyperthermia. J. Cancer Res. Clin. Oncol. 127:2001;425-432.
15. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 108:1995;1122-1128.
16. Robins H.I., Dennis W.H., Neville A.J., et al. A nontoxic system for 41.8 degrees C whole-body hyperthermia: results of a phase I study using a radiant heat device. Cancer Res. 45:1985;3937-3944.
17. Bakhshandeh A., Bath V., Wiedemann G.J., et al. Year 2000 guidelines for clinical practice of whole-body hyperthermia combined with cytotoxic drugs from the University of Lübeck and the University of Wisconsin. J. Oncol. Pharm. Pract. 5:1999;131-134.
18. Robins H.I., Schmitt-Tiggelaar C.L., Cohen J.D., et al. A new technological approach to radiant heat whole body hyperthermia. Cancer Lett. 79:1994;137-145.
19. Wiedemann G.J., Robins H.I., Gutsche S., et al. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. Eur. J. Cancer. 32A:1996;888-892.
20. Rusch V.W., Venkatraman E.S. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thoracic Surg. 68:1999;1799-1804.
21. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J. Clin. Oncol. 16:1998;145-152.
22. Byrne M.J., Davidson J.A., Musk A.W., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J. Clin. Oncol. 17:1999;25-30.
23. Kindler H.L., van Meerbeeck J.P. The role of gemcitabine in the treatment of malignant mesothelioma. Semin. Oncol. 29:2002;70-76.
24. Thödtmann R., Depenbrock H., Dumez H., et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 17:1999;3009-3016.
25. Vogelzang N.J., Rusthoven J., Paoletti P., et al. Phase III single-blinded study of pemetrexed+cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 12:2002;2a. abstract #5.
26. Mikulski S.M., Costanzi J.J., Vogelzang N.J., et al. Phase II trial of single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. 20:2001;274-281.
27. Parra H.S., Tixi L., Latteri F., et al. Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer. 92:2001;650-656.
28. Katschinski D.M., Wiedemann G.J., Longo W., d'Oleire F.R., Spriggs D., Robins H.I. Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. Cytokine Growth Factor Rev. 10:1999;93-97.
29. Robins H.I., Cohen J.D., Schmitt C.L., et al. Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients. J. Clin. Oncol. 11:1993;1787-1794.
30. Mbidde E.K., Harland S.J., Calcert A.H., et al. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother. Pharmacol. 18:1986;284-285.
31. Raghavan D., Gianoutsos P., Bishop J., et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J. Clin. Oncol. 8:1990;151-154.
32. Westermann AM, Wiedemann GJ, Jager E, et al. A systemic hyperthermia oncologic working group trial: ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole body hyperthermia for metastatic soft tissue sarcoma, submitted for publication.
33. Gerad H., Egorin M.J., Whitacre M., et al. Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia. Cancer Chemother. Pharmacol. 11:1983;162-166.
34. Ohno S., Siddik Z.H., Baba H., et al. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res. 51:1991;2994-3000.